Meanwhile, myeloid-directed therapies such as the CSF1R inhibitor Pexidartinib (FDA-approved for tenosynovial giant cell tumor), CCR5 antagonist Maraviroc (approved for HIV), and the dual CCR2/CCR5 antagonist BMS-813160 (Phase II, metastatic CRC; NCT03184870) offer promising options to curb macrophage-driven immune tolerance. This evidence concerns the gene CCR5 and giant cell tumor.